Baird talks Sarepta, sees FDA biopsy request as bullish

Baird is out with some positive commentary on Sarepta Therapeutics (SRPT +1.2%) following management meetings.

The FDA's request for a fourth biopsy is a "bullish signal" in Baird's view, as the firm "finds it hard to believe [the regulator] would request [an] invasive procedure unless the results would carry very substantial weight." (previous)

What SRPT investors do not want, according to Baird, is either "complete failure or overwhelming success" for Prosensa (RNA -0.4%) and GlaxoSmithKline's (GSK +0.1%) drisapersen (DEMAND-III top-line results are due soon), as either "would be a hard blow to the bull thesis."

Not to worry though (if you're an SRPT bull), Baird sees "safety issues and inconsistent pharmacological activity" for drisapersen as positive for eteplirsen.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs